• 1
    Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. Aug 4 2004; 44(3): 720732.
  • 2
    Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. May 12 1998; 97(18): 18371847.
  • 3
    Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. Nov 28 1986; 256(20): 28232828.
  • 4
    The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. Jan 20 1984; 251(3): 365374.
  • 5
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. May 27 1998; 279(20): 16151622.
  • 6
    Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. Apr 5 2003; 361(9364): 11491158.
  • 7
    Ferrieres J. Effects on coronary atherosclerosis by targeting low-density lipoprotein cholesterol with statins. Am J Cardiovasc Drugs. 2009; 9(2): 109115.
  • 8
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. Dec 17 2002; 106(25): 31433421.
  • 9
    Luscher T, Tanner F, Tschudi M, Noll G. Endothelial dysfunction in coronary artery disease. Ann Rev Med. 1993; 44: 395418.
  • 10
    Yasue H, Matsuyama K, Matsuyama K, Okumura K, Morikami Y, Ogawa H. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment. Possible role of early coronary atherosclerosis. Circulation. 1990; 81: 482490.
  • 11
    Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf). Jun 2009; 196(2): 193222.
  • 12
    Holland JA, Meyer JW, Schmitt ME, Sauro MD, Johnson DK, Abdul-Karim RW, Patel V, Ziegler LM, Schillinger KJ, Small RF, et al. Low-density lipoprotein stimulated peroxide production and endocytosis in cultured human endothelial cells: mechanisms of action. Endothelium. 1997; 5(3): 191207.
  • 13
    Alderson LM, Endemann G, Lindsey S, Pronczuk A, Hoover RL, Hayes KC. LDL enhances monocyte adhesion to endothelial cells in vitro. Am J Pathol. May 1986; 123(2): 334342.
  • 14
    Casino P, Kilcoyne C, Quyyumi A, Hoeg J, Panza J. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation. 1993; 88: 25412547.
  • 15
    Casino PR, Kilcoyne CM, Cannon RO, 3rd, Quyyumi AA, Panza JA. Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolemia extends beyond the muscarinic receptor. Am J Cardiol. 1995; 75(1): 4044.
  • 16
    Chowienczyk P, Watts G, Cockcroft J, Ritter J. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolemia. Lancet. 1992; 340: 14301432.
  • 17
    Weil BR, Stauffer BL, Greiner JJ, DeSouza CA. Prehypertension is associated with impaired nitric oxide-mediated endothelium-dependent vasodilation in sedentary adults. Am J Hypertens. Sep 2011; 24(9): 976981.
  • 18
    Steinberg H, Chaker H, Leaming R, Johnson A, Brechtel G, Baron A. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest. 1996; 97: 26012610.
  • 19
    Lohman T, Roche A, Mortorell R. Athropometric Standardization Reference Manual. Champaign , IL : Human Kinetics; 1988.
  • 20
    Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, Desouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring). Dec 2006; 14(12): 21272131.
  • 21
    DeSouza C, Jones P, Seals D. Physical activity status and age-related differences in coagulation and fibrinolytic factors in women. Arterioscler Thromb Vasc Biol. 1998; 18: 362368.
  • 22
    DeSouza C, Clevenger C, Greiner J, Smith D, Hoetzer G, Shapiro L, Stauffer B. Evidence for agonist-specific endothelial vasodilator dysfunction with ageing in healhty humans. J Physiol (London). 2002; 542: 255262.
  • 23
    Walker AE, Eskurza I, Pierce GL, Gates PE, Seals DR. Modulation of vascular endothelial function by low-density lipoprotein cholesterol with aging: influence of habitual exercise. Am J Hypertens. Mar 2009; 22(3): 250256.
  • 24
    Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. Jan 25 2005; 111(3): 363368.
  • 25
    Beckman JA, Creager MA. The nonlipid effects of statins on endothelial function. Trends Cardiovasc Med. Jul 2006; 16(5): 156162.
  • 26
    Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. Investigation of decreased availability of nitric oxide precursor as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. J Am Coll Cardiol. Mar 15 1994; 23(4): 844850.
  • 27
    Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. Nov 5 1999; 274(45): 32,51232,519.
  • 28
    Wang W, Hein TW, Zhang C, Zawieja DC, Liao JC, Kuo L. Oxidized low-density lipoprotein inhibits nitric oxide-mediated coronary arteriolar dilation by up-regulating endothelial arginase I. Microcirculation. Jan 2011; 18(1): 3645.
  • 29
    Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest. Jan 1992; 89(1): 1018.
  • 30
    Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Ann Rev Physiol. 1999; 61: 391415.
  • 31
    Cardillo C, Kilcoyne C, Cannon R, Panza J. Increased activity of endougenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol. 2000; 36: 14831488.
  • 32
    Best P, mcKenna C, Hasdai D, Holmes D, Lerman A. Chronic endothelin-receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation. 1999; 99: 17471752.
  • 33
    Best PJ, Lerman LO, Romero JC, Richardson D, Holmes DR, Jr., Lerman A. Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro. Arterioscler Thromb Vasc Biol. Nov 1999; 19(11): 27692775.
  • 34
    Superko HR, Gadesam RR. Is it LDL particle size or number that correlates with risk for cardiovascular disease? Curr Atheroscler Rep. Oct 2008; 10(5): 377385.